These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials. Hakeem A; Marmagkiolis K; Hacioglu Y; Uretsky BF; Gundogdu B; Leesar M; Bailey SR; Cilingiroglu M Cardiovasc Revasc Med; 2013; 14(6):349-55. PubMed ID: 24080379 [TBL] [Abstract][Full Text] [Related]
6. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials. Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522 [TBL] [Abstract][Full Text] [Related]
7. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke. Wiktor DM; Carroll JD Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380 [TBL] [Abstract][Full Text] [Related]
8. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412 [TBL] [Abstract][Full Text] [Related]
9. Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials. Schulze V; Lin Y; Karathanos A; Brockmeyer M; Zeus T; Polzin A; Perings S; Kelm M; Wolff G Clin Res Cardiol; 2018 Sep; 107(9):745-755. PubMed ID: 29500568 [TBL] [Abstract][Full Text] [Related]
10. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929 [TBL] [Abstract][Full Text] [Related]
11. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132 [TBL] [Abstract][Full Text] [Related]
12. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials. Wang TKM; Wang MTM; Ruygrok P Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754 [TBL] [Abstract][Full Text] [Related]
13. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events. Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911 [TBL] [Abstract][Full Text] [Related]
14. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. Kwong JS; Lam YY; Yu CM Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879 [TBL] [Abstract][Full Text] [Related]
15. Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials. Riaz H; Khan MS; Schenone AL; Waheed AA; Khan AR; Krasuski RA Am Heart J; 2018 May; 199():44-50. PubMed ID: 29754665 [TBL] [Abstract][Full Text] [Related]
16. Iatrogenic erosion of the septum primum resulting in an atrial septal defect with left-to-right shunt: a rare pitfall of patent foramen ovale percutaneous closure. Scacciatella P; Biava LM; Marra S Catheter Cardiovasc Interv; 2014 Sep; 84(3):494-6. PubMed ID: 24399577 [TBL] [Abstract][Full Text] [Related]